Musi wa7 Kukadzi, 2025, Sichuan Kelun-Biotech Biopharmaceutical yakazivisa kubvumidzwa kweCetuximab N01 Injection yayo neNational Medical Products Administration yekurapa kenza yemudumbu yakapararira (mCRC) muChina.
Kubvumidzwa uku kwakavakirwa paongororo yakakura yekiriniki yechikamu chechitatu inoratidza kushanda uye kuchengetedzeka kwemushonga uyu zvakaenzana nekurapa kuripo, zvichigona kuwedzera mukana wekurapa mCRC muChina uko kuwanda kwehuwandu hwevanhu vanofa nechirwere ichi kuri kuwedzera.
Chidzidzo ichi chaisanganisira varwere vanosvika 688, uye mhedzisiro yacho yakaratidza kuti mushonga we cetuximab N01 waive wakaenzana ne cetuximab injection (ORR) zvichienzaniswa ne cetuximab injection (Erbitux) combined chemotherapy (ORR). Objective response rate (ORR) ye cetuximab N01 ne cetuximab injection (Erbitux) yaive 71.0% uye 77.5%, zvichiteerana. Pakanga pasina musiyano wakakosha mu response duration (DoR) uye progression free survival (PFS) pakati pe cetuximab N01 ne cetuximab injection (Erbitux), ne avhareji ye progression free survival yemwedzi 10.9 nemwedzi 10.8, zvichiteerana.
Panyaya yekuchengetedzeka, bvunzo iyi yekiriniki yakakura yechikamu chechitatu inosimbisa zvizere kuti mushonga we cetuximab N01 unosanganiswa nekemotherapy wakaenzana pakuchengetedza, kushivirira, uye simba rekudzivirira muviri zvichienzaniswa nekemotherapy yakasanganiswa yecetuximab injection (Erbitux).
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Mareferensi
1.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250207150842162.html
2.Wu CC, Hsu CW, Hsieh MC, nevamwe. Kutevedzana Kwakanaka uye Kurapwa Kwevarwere Vane RAS Wild-Type Metastatic Colorectal Cancer: Kuongorora Kunochinja-chinja. J Clin Med. 2021 Mbudzi 4;10(21):5166.
Nguva yekutumira: Kukadzi-13-2025